Figure 2From: Dynamic tumor modeling of the dose–response relationship for everolimus in metastatic renal cell carcinoma using data from the phase 3 RECORD-1 trial Simulated changes in tumor size over 1 year in the average patient treated continuously with either placebo or everolimus (5 or 10 mg daily). Back to article page